期刊文献+

垂体瘤伴腺垂体功能减退诊疗进展 被引量:1

Evaluation and Replacement of Hypo-pituitary in Pituitary Tumor
在线阅读 下载PDF
导出
摘要 本文综述了垂体瘤手术前后腺垂体功能减退的诊断和治疗,着重讨论生长激素(GH)/胰岛素样生长因子(IGF)轴、催乳素(PRL)、促甲状腺激素(TSH)轴、促肾上腺皮质激素(ACTH)轴(不包括下丘脑-垂体-性腺轴的内容)。目前临床上,存在着不少甲状腺激素替代不充分或糖皮质激素超量使用的现象,一定程度上影响着垂体瘤的治疗效果。手术前后对甲状腺和肾上腺轴功能进行准确评估对于垂体瘤患者的合理治疗显得十分重要。本文全面综述了近年来TSH和ACTH轴功能低下的评估和替代治疗的新观点。此外,GH轴在垂体前叶功能减退时最易受累.临床上常容易忽视GH激素缺乏的评估和治疗,成人GH合理补充治疗能有效改善患者身体组成和骨健康,降低心血管疾病风险,提高生活质量。本文一并讨论了成人GH合理补充的方法,认为长期规范随访和及时调整药物剂量十分必要。 We reviewed the evaluation and replacement of hypo-pituitary before or after pituitary tumor surgery, focusing on the growth hormone (GH) / insulin-like growth factor (IGF) axis, prolactin (PRL), thyroid stimulating hormone (TSH) axis, and adrenocorticotropic cortical hormone (ACTH) axis, not including the hypothalamic-pituitary-gonadal axis that will be discussed in another review. In clinics, there existed insufficient thyroid hormone replacement and over dosage of corticosteroid, which impacted on the treatment of pituitary tumor. So, functional evaluation of pituitary-adrenal and pituitary-thyroid axis are critical for patients with pituitary tumors. Here we supplied with the new ideas involved in the two axis. In addition, GH deficiency is most likely to happen and to be ignored in pituitary adenoma. Reasonable GH administration would improve the patient's body composition, bone health, quality of life, and reduce the risk of cardiovascular disease. This review also discussed the reasonable replacement of GH. The long-term follow-up and timely dose adjustment for all hormones are required.
出处 《中国神经肿瘤杂志》 2013年第4期230-235,共6页 Chinese Journal of Neuro-Oncology
基金 上海诺华贸易有限公司项目研究[No.Original 2013(2618)-OBU(505)-10(272)]
关键词 垂体瘤 腺垂体功能减退 替代疗法 Pituitary tumor Hypopituitarism Replacement therapy
  • 相关文献

参考文献16

  • 1惠国桢.垂体瘤[M].北京:人民军医出版社,2005:35-38.
  • 2Larsen PR.Williams textbook of Endocrinology 10th ed[M].Saunders,2002:252-267.
  • 3Fatemi N,Dusick JR,Mattozo C,et al.Pituitaryhormonal loss and recovery after transsphenoidal adenomaremoval[J].Neurosurgery,2008,63:709-718.
  • 4Ur E,Serri 0,Legg K,et al.Canadian guidelines forthe managenment of adult growth hormone deficiency [J].Clin Invest Med,2006,29(2):83-90.
  • 5Reimondo G,Bovio S,Allasino B,et al.Secondary hypoadrenalism[J].Pituitary,2008,11(2):147-154.
  • 6Markkanen HM,Pekkarinen T,Valim aki MJ,et al.Comparison of two growth hormone stimulation tests and their cut-off limits in healthy adults at an outpatient clinic[J].Growth Horm IGF Res,2013,23(5):165-169.
  • 7Molitch ME,Clemmons DR,Malozowski S,et al.Evaluation and treatment of adult growth hormone deficiency:an Endocrine Society clinical practice guideline [J].Clin Endocrinal Metab,2010,96:1587-1609.
  • 8岑晶,顾锋.成人生长激素缺乏症诊断与治疗指南解读[J].中国实用内科杂志,2011,31(8):608-612. 被引量:10
  • 9Balbach L,Wallaschofski H,V?lzke H,et al.Serumprolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes [J]? BMC Endocr Disord,2013,13(12):1-8.
  • 10Garber JR,Cobin RH,Gharib H,et al.Clinical practiceguidelines for hypothyroidism in adults:cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association [J].Endocr Pract,2012,18(6):988-1028.

二级参考文献9

  • 1Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency : an Endocrine Society Clinical Practice Guideline[ J]. J Clin Endocrinol Metab,2006,91 (5) :1621 -1634.
  • 2Ho KK. Consensus guidelines for the diagnosis and treatment of a- dults with GH deficiency II :a statement of the GH Research Soci- ety in association with the European Society for Pediatric Endocri- nology, Lawson Wilkins Society, European Society of Endocrinolo- gy,Japan Endocrine Society, and Endocrine Society of Australia [ J ]. Eur J Endocrinol,2007,157 ( 6 ) :695 - 700.
  • 3Cook DM, Yuen KC, Biller BM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients - 2009 update [ J ]. Endocr Pract, 2009, 15 (Sappl 2) :1 -29.
  • 4Stochhohn K, Gravholt CH,Laursen T,et al. Mortality and GH de- ficiency : a nationwide study [ J ]. Eur J Endocrinol,2007,157 ( 1 ) : 9-18.
  • 5Yuen KC, Biller BM, Molitch ME, et al. Clinical review : Is lack of recombinant growth hormone (GH) -releasing hormone in the Unit- ed States a setback or time to consider glucagon testing tor adult GH deficiency? [ J ]. J Clin Endocrinol Metab, 2009, 94 ( 8 ) : 2702 - 2707.
  • 6Giavoli C, Libe R, Corbetta S, et al. Effect of recombinant human growth hormone(GH) replacement on the hypothalamic-pituitary- adrenal axis in adult GH-deficient patients [ J ]. J Clin Endoerinol Metab,2004,89 ( 11 ) :5397 - 5401.
  • 7Porretti S,Giavoli C,Ronchi C,et al. Recombinant human GH re- placement therapy and thyruid function in a large group of adult GH-deficient patients:when does L-T(4) therapy become manda- tory ? [ J ]. J Clin Endocrinol Metab,2002,87 (5) :2042 - 2045.
  • 8Clemmons DR. The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity [ J ]. J Clin Invest, 2004, 113 ( 1 ) : 25 - 27.
  • 9Svensson J and Bengtsson BA. Safety aspects of GH replacement [ J ]. Eur J Endocrinol,2009,161 ( Suppl 1 ) S65 - 74.

共引文献9

同被引文献5

引证文献1

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部